Skip to Main Content
Skip Nav Destination

BTK Degradation Overcomes Recurrent BTK Mutations in B-Cell Malignancies

February 8, 2024

Major Finding: The BTK degrader NX-2127 targets kinase-dependent and -independent BTK activity in B-cell malignancies.

Concept: NX-2127 prevents kinase-impaired mutants from functioning as a scaffold that promotes B-cell activation.

Impact: This study highlights the potential of NX-2127 to treat relapsed or refractory B-cell malignancies. 

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal